Prevalence And Burden Of Nausea And Vomiting In Pregnant Women

NCT ID: NCT04926727

Last Updated: 2021-09-05

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

600 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-10-04

Study Completion Date

2022-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

On February 25th, 2019, ITALFARMACO launched Nuperal® in Italy, an association of doxylamine succinate and pyridoxine hydrochloride authorized by AIFA for the symptomatic treatment of nausea and vomiting in pregnancy (NVP). This drug is also recommended as first choice drug therapy by the American College of Obstetricians and Gynecologists (ACOG) Guidelines and is supported by extensive international literature.

Numerous epidemiological researches conducted in the US and Norway have highlighted the extent of vomiting and pregnant nausea. Unfortunately to date, there are no information on the prevalence of this phenomenon in Italy, on its impact on women's lives and on the interaction between woman and gynecologists.

The research hypothesis of the present survey is that, using a representative sample of pregnant women in Italy, it will be possible to identify the prevalence and weight of nausea and vomiting symptoms during pregnancy in this country. The study is an open, non-comparative, multicenter survey and the aim is to evaluate the prevalence and weight that the symptoms of nausea and vomiting have in pregnant women in Italy.

The study population will include 600 women found during weeks 18-22 of pregnancy who will arrive at the three sites or will contact the Investigators after the Ethics Committee (EC) approval.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Nausea Gravidarum Vomiting of Pregnancy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

OTHER

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Pregnant women

600 Pregnant women between the 18th and 22nd week.

* 200 from Northern Italy;
* 200 from Central Italy;
* 200 from Southern Italy and the Islands.

Survey

Intervention Type OTHER

Observational study

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Survey

Observational study

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Caucasian women in physiological pregnancy and between the 18th and 22nd week (time of morphological ultrasound).
* Women able to communicate adequately with the interviewer and understand the questionnaires.
* Women able to understand and who can provide valid informed consent to the Survey.

Exclusion Criteria

* Twin pregnancy.
* Medically assisted procreation (MAP)
Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Opera CRO, a TIGERMED Group Company

OTHER

Sponsor Role collaborator

Italfarmaco

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Policlinico di Napoli - Università di Napoli "Federico II"

Napoli, Corso Umberto I 40, Italy

Site Status

P.O. SS.ma Annunziata di Chieti della ASL di Chieti

Chieti, Via Dei Vestini, Italy

Site Status

Ospedale dei Bambini "Vittore Buzzi"

Milan, Via Lodovico Castelvetro, 32, Italy

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Italy

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Dionisio F Barattini, MD Europe, Opera CRO

Role: CONTACT

+39 3355437574

Simone Guadagna, Clinical Project Manager

Role: CONTACT

+39 3511251844

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

OPITA/0120/SU

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Domperidone for Chronic Nausea and Vomiting
NCT02757534 NO_LONGER_AVAILABLE
The Montefiore Metoclopramide Study
NCT00475306 COMPLETED PHASE4